While the precise effects of these mutations on AR activity, or the responsiveness of PCa cells to ADT have not been established, it is conceivable that multiple somatic alterations in the AR gene as well as its upstream regulators and downstream targets could have cumulative or synergistic effects that ultimately undermine efficacy of AR-targeted therapy. This evidence concerns the gene AR and posterior cortical atrophy.